Table 6.
Follow-up data.
| Pt | PEmb-Qol score |
Symptoms of PE | Information on taking medicine at home | Re-examination results of CTPA | Re-examination results of ultrasound | Follow-up time (months) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FO | AD | WR | SL | IO | EC | ||||||
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | None | Rivaroxaban, 3 months | Normal | Normal | 37 |
| 2 | 1 | 1 | 1 | 1 | 1 | 1 | None | Rivaroxaban, 6 months | Normal | Normal | 18 |
| 3 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 4 | 1 | 1 | 1 | 1 | 1 | 1 | None | Rivaroxaban, 3 months | Normal | Normal | 28 |
| 5 | 1.1 | 1.1 | 1 | 1 | 1 | 1 | Chest distress sometimes when running | Rivaroxaban, 1 months | Normal | Normal | 15 |
| 6 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 7 | 1 | 1 | 1 | 1 | 1 | 1 | None | Warfarin, 35 months | Normal | Normal | 35 |
| 8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FO, frequency of complaints; AD, ADL (ADL, activities of daily living) limitations; WR, work-related problems; SL, social limitations; IO, intensity of complaints; EC, emotional complaints; PE, pulmonary embolism; CTPA, computed tomographic pulmonary arteriography.